title: Management of recurrent testicular germ cell tumors.
abstract: Although front-line chemotherapy cures most men with testicular germ cell tumors, salvage therapy is still important in a small but significant minority. Second-line conventional-dose or high-dose chemotherapy with stem cell rescue may cure 25%-50% of patients. New chemotherapeutic agents, including the taxanes gemcitabine and oxaliplatin, have added to the therapeutic armamentarium. Salvage surgical resection has an important role in selected patients. Cisplatin-refractory patients have a poor prognosis with current therapy, and novel chemotherapeutic and biologic agents need to be discovered for such patients.
authors.affiliation: US Oncology Research, Houston, Texas, USA. guru.sonpavde@usoncology.com
authors.forename: Guru
authors.initials: G
authors.lastname: Sonpavde
authors.forename: Thomas E
authors.initials: TE
authors.lastname: Hutson
authors.forename: Bruce J
authors.initials: BJ
authors.lastname: Roth
mesh_terms: D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D011379:Prognosis; D016879:Salvage Therapy / Q000379:methods*; D033581:Stem Cell Transplantation; D013736:Testicular Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D016896:Treatment Outcome